Landos Leverages Advanced Computing For Autoimmune Disease Drug Development
Executive Summary
Emerging Company Profile: Start-up Landos is raising money through a Series B financing to fund Phase II development of its lead oral, gut-restricted compound and described its plans in a video interview at the Biotech Showcase in San Francisco in January.
You may also be interested in...
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Finance Watch: Landos Raises $60m Series B Round Ahead Of Phase II Data In 2020
If Landos goes public late next year, its financing strategy will align with venture capital and IPO trends observed in a new Jefferies report. Also, D&D Pharmatech raises $137.1m in VC cash, Sonnet secures up to $100m and the CF Foundation commits up to $15m to Arcturus.
Theravance Banks $100m As J&J Bets Big On IBD Drug
If the JAK inhibitor codenamed TD-1473 proves effective in Crohn’s disease and ulcerative colitis, the clinical, regulatory and commercial know-how in IBD from partner Janssen could help Theravance pocket $1bn.